ED
Etzer Darout Guggenheim Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
|
IVA
1
Inventiva
IVA
$775M
| $5.57 | $13 |
133%
upside
| Buy | 5 days ago |
|
2
Scholar Rock
SRRK
$3.02B
| $31.41 | $45 |
43%
upside
| Outperform | 1 month ago |
|
3
Terns Pharmaceuticals
TERN
$632M
| $7.22 | $15 |
108%
upside
| Outperform | 3 months ago |
|
4
Arvinas
ARVN
$575M
| $7.83 | $20 |
155%
upside
| Outperform | 5 months ago |
|
5
Protagonist Therapeutics
PTGX
$3.77B
| $60.53 | $72 |
19%
upside
| Outperform | 6 months ago |
|
6
BioNTech
BNTX
$27B
| $112.46 | $143 |
27%
upside
| Outperform | 6 months ago |
|
7
Merus
MRUS
$5.1B
| $67.47 | $96 |
42%
upside
| Outperform | 6 months ago |
|
8
Exelixis
EXEL
$10.2B
| $37.88 | $40 |
6%
upside
| Market Perform | 8 months ago |
|
9
Tourmaline Bio
TRML
$687M
| $26.74 | $50 |
87%
upside
| Outperform | 9 months ago |
|
10
Nurix Therapeutics
NRIX
$758M
| $9.91 | $35 |
253%
upside
| Outperform | 9 months ago |
|
11
Kymera Therapeutics
KYMR
$3.11B
| $43.51 | $55 |
26%
upside
| Market Perform | 9 months ago |
|
12
Nuvalent
NUVL
$5.83B
| $80.89 | $134 |
66%
upside
| Outperform | 9 months ago |
|
13
Xencor
XNCR
$610M
| $8.55 | $34 |
298%
upside
| Outperform | 10 months ago |
|
14
Genmab
GMAB
$16.9B
| $27.54 | $48 |
74%
upside
| Outperform | 10 months ago |
|
15
Novartis
NVS
$251B
| $129.73 | $120 |
8%
downside
| Market Perform | 10 months ago |
|
16
Y-mAbs Therapeutics
YMAB
$390M
| $8.58 | $25 |
191%
upside
| Outperform | 1 year ago |
|
17
CytomX Therapeutics
CTMX
$376M
| $2.28 | $3.59 |
57%
upside
| Market Perform | 1 year ago |
|
18
AstraZeneca
AZN
$253B
| $81.70 | $82 |
0%
upside
| Outperform | 1 year ago |
|
19
Foghorn Therapeutics
FHTX
$326M
| $5.77 | $19 |
229%
upside
| Outperform | 2 years ago |
|
20
Alnylam Pharmaceuticals
ALNY
$59.2B
| $452 | $170 |
62%
downside
| Buy | 3 years ago |
|
21
Akero Therapeutics
AKRO
$3.58B
| $44.72 | $54 |
21%
upside
| Buy | 4 years ago |
|
22
Mirum Pharmaceuticals
MIRM
$3.82B
| $76.06 | $38 |
50%
downside
| Buy | 5 years ago |
|